Monoclonal Antibody May Benefit Patients With Kidn
Post# of 148112
(Total Views: 462)
Posted On: 05/29/2024 1:56:56 PM
Monoclonal Antibody May Benefit Patients With Kidney Transplant Rejection
An investigational monoclonal antibody appeared to have therapeutic benefits among kidney transplant patients with antibody-mediated rejection, a randomized phase II trial showed.
After 24 weeks, resolution of morphologic antibody-mediated rejection occurred in nine of the 11 participants who received infusions of the CD38 monoclonal antibody felzartamab compared with two of 10 placebo-treated participants, reported Georg Böhmig, MD, of the Medical University of Vienna, and colleagues in the New England Journal of Medicine.
Originally developed for multiple myeloma, felzartamab is a fully human IgG1 monoclonal CD38 antibody that depletes target cells through antibody-dependent cellular cytotoxicity and phagocytosis.
https://www.medpagetoday.com/nephrology/kidne...ate_active
Ohm's list includes chronic kidney disease (due to inflammation). After Leronlimab is available for kidney disease, there will hopefully be fewer kidney transplants. Where transplants are necessary, Leronlimab may be needed on a long-term basis. The article included the following comment:
Discussion of week 52 means this requires a very long study. When the buyout ultimately comes, I look forward to seeing various posters' thoughts on buying shares in whoever does the buyout. I suspect ohm would say that research will develop many more possibilities than his list of 90. Many of those, however, will require long trials.
I don't want to jinx a buyout, but one would think that purchasing stock in the buyer would be a good long-term investment.
An investigational monoclonal antibody appeared to have therapeutic benefits among kidney transplant patients with antibody-mediated rejection, a randomized phase II trial showed.
After 24 weeks, resolution of morphologic antibody-mediated rejection occurred in nine of the 11 participants who received infusions of the CD38 monoclonal antibody felzartamab compared with two of 10 placebo-treated participants, reported Georg Böhmig, MD, of the Medical University of Vienna, and colleagues in the New England Journal of Medicine.
Originally developed for multiple myeloma, felzartamab is a fully human IgG1 monoclonal CD38 antibody that depletes target cells through antibody-dependent cellular cytotoxicity and phagocytosis.
https://www.medpagetoday.com/nephrology/kidne...ate_active
Ohm's list includes chronic kidney disease (due to inflammation). After Leronlimab is available for kidney disease, there will hopefully be fewer kidney transplants. Where transplants are necessary, Leronlimab may be needed on a long-term basis. The article included the following comment:
Quote:
However, treatment effects were not durable after discontinuation, with three of nine patients responsive to felzartamab having a recurrence of antibody-mediated rejection by week 52, along with an increase in molecular activity and biomarker levels toward baseline levels.
Discussion of week 52 means this requires a very long study. When the buyout ultimately comes, I look forward to seeing various posters' thoughts on buying shares in whoever does the buyout. I suspect ohm would say that research will develop many more possibilities than his list of 90. Many of those, however, will require long trials.
I don't want to jinx a buyout, but one would think that purchasing stock in the buyer would be a good long-term investment.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼